B Cell Immunomodulatory Therapy for ARDS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Acute Respiratory Distress Syndrome (ARDS) are inadequate, with high mortality rates and significant long-term morbidity, and existing pharmacologic agents have shown neutral or deleterious effects, necessitating a new therapeutic approach.
Innovation Solution
Administration of isolated, purified, or modified B cells, including Breg cells expressing immunomodulatory cytokine IL-10, to mitigate inflammation and improve lung function in subjects with ARDS, potentially combined with other therapeutics such as antiviral or anti-inflammatory drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If pharmacologic agents are used to treat ARDS, then treatment options are provided, but the agents show neutral or deleterious effects
Solution Approach 1:
The patent uses B cells as intermediary cells that mediate the therapeutic effect between the administered composition and the ARDS pathology. These B cells act as biological mediators that modulate the immune response and reduce inflammation in the lungs, providing a more reliable treatment mechanism compared to direct pharmacologic intervention.
Solution Approach 2:
The treatment leverages the body's own immune system components (B cells) to fight the disease. By administering compositions that enhance or restore B cell function, the therapy enables the patient's immune system to self-regulate and combat ARDS, rather than relying on external pharmacologic agents that may have adverse effects.
2Reliability
If intensive care and mechanical ventilation are provided to ARDS patients, then respiratory support is maintained, but mortality rate remains high at 35-46%
Solution Approach 1:
The patent employs B cell therapy as a preliminary or adjunctive treatment to reduce inflammation and immune damage before it progresses to severe respiratory failure requiring mechanical ventilation. By acting early in the disease course, the therapy aims to prevent the need for intensive care interventions and reduce mortality risk.
Solution Approach 2:
The therapy converts the harmful overactive immune response that causes ARDS into a beneficial controlled response. By modulating B cell activity, the treatment transforms the pathological inflammation into a regulated immune response that protects lung tissue while maintaining respiratory function.
3Object-affected harmful factors
If no specific pharmacologic treatment is given for ARDS, then avoidance of drug side effects is maintained, but no treatment options are available to reduce morbidity
Solution Approach 1:
The patent changes the fundamental parameter of treatment from chemical pharmacologic agents to biological cell-based therapy. This parameter change allows for immunomodulation through B cell mechanisms rather than through drug-receptor interactions, avoiding pharmacologic side effects while providing active treatment to reduce morbidity and mortality.
Data Source
AI summary
Disclosed are methods of treating Acute Respiratory Distress Syndrome using B cells, e.g., by administering B cells to a subject in need thereof.